This research showed that in conjunction with silibinin, piceatannol (a JAK1 inhibitor) lessened STAT3 phosphorylation at Tyr705 and thus triggered caps, which induced the programmed cell death of prostate cancer cells [135]. Here, STAT3 is linked to prostate cancer.